Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

Oct. 30, 2024 — The amount of money people pay out-of-pocket for branded drugs to treat neurological diseases like multiple sclerosis (MS), Alzheimer's, and Parkinson's disease continues to rise, ...

Experts made the discovery after analysing hours of YouTube footage of celebrities with the disease - and it paves the way ...

The following column was originally published on Feb. 25, 2022. Thanks to breakthroughs in medicine and nutrition in recent years, we are living longer than ever before. But this increase in life ...

Some Diabetes Drugs Tied to Lower Risk of Dementia ... Researchers Target Neurogenesis in New Approach to Treat Parkinson's Disease Apr. 30, 2024 — Researchers have found a way to better ...

Subscribe to Here’s the Deal, our politics newsletter for analysis you won’t find anywhere else.

Analysis suggests that the research and development of DMTs and non-motor therapies will diversify Parkinson's treatment ...

AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy ... compared to treatment with immediate-release carbidopa/levodopa. The drug also achieved a significant ...

Aphrodisiacs are foods or substances that are believed to boost our sex drive and enhance sexual pleasure and performance.

Nilotinib, a blood cancer medicine, was previously shown to improve movement and mental function in a small group of patients with Parkinson's disease-related dementia and Lewy body dementia.